Atara Biotherapeutics, Inc. (ATRA): Isaac E. Ciechanover , Chief Executive Officer of Atara Biotherapeutics, Inc. sold 9,600 shares on Jun 23, 2016. The Insider selling transaction was reported by the company on Jun 27, 2016 to the Securities and Exchange Commission. The shares were sold at $21.25 per share for a total value of $204,048.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Jun 8, 2016, Isaac E. Ciechanover (Chief Executive Officer) sold 12,000 shares at $20.65 per share price.On May 18, 2016, Gad Soffer (Chief Operating Officer) sold 5,427 shares at $15.91 per share price.Also, On May 18, 2016, Christopher Haqq (Chief Medical Officer) sold 1,605 shares at $15.57 per share price.On May 18, 2016, Carol Giltner Gallagher (director) sold 1,184 shares at $15.96 per share price.
Shares of Atara Biotherapeutics Inc (ATRA) ended Friday, Jun 24, 2016 session in red amid volatile trading. The shares closed down -0.58 points or -2.63% at $21.48 with 13,86,081 shares getting traded. Post opening the session at $20.75, the shares hit an intraday low of $20.04 and an intraday high of $21.94 and the price vacillated in this range throughout the day. The company has a market cap of $617 M and the number of outstanding shares has been calculated to be 2,87,44,466 shares. The 52-week high of Atara Biotherapeutics Inc is $65.5599 and the 52-week low is $13.31.
Atara Biotherapeutics Inc. is a clinical stage biopharmaceutical company. The Company is focused on developing therapeutics for serious unmet medical needs with an initial focus on muscle wasting conditions and oncology. The Company’s lead product candidate PINTA 745 is a peptibody that binds myostatin and inhibits its corresponding signal transduction thereby blocking the negative regulation of skeletal muscle growth. PINTA 745 is in a Phase II clinical trial. The Company’s second product candidate STM 434 which is in a Phase I clinical study is a soluble ActR2B receptor that binds Activin A. The Company has five additional product candidates: ATA 842 a humanized antibody targeting myostatin; ATA 777 a fully human antibody targeting Activin A; ATA M43 a fully human anti-ActR2A/2B monoclonal antibody; STM 217 a soluble ActR2B receptor-IgG Fc fusion protein and a close analog of STM 434 and ActR2B5 a soluble ActR2B receptor that can be fused to an IgG Fc receptor.